Dong Songtao, Guo Xiangnan, Han Fei, He Zhonggui, Wang Yongjun
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Acta Pharm Sin B. 2022 Mar;12(3):1163-1185. doi: 10.1016/j.apsb.2021.08.020. Epub 2021 Aug 21.
Cancer immunotherapy has become a new generation of anti-tumor treatment, but its indications still focus on several types of tumors that are sensitive to the immune system. Therefore, effective strategies that can expand its indications and enhance its efficiency become the key element for the further development of cancer immunotherapy. Natural products are reported to have this effect on cancer immunotherapy, including cancer vaccines, immune-check points inhibitors, and adoptive immune-cells therapy. And the mechanism of that is mainly attributed to the remodeling of the tumor-immunosuppressive microenvironment, which is the key factor that assists tumor to avoid the recognition and attack from immune system and cancer immunotherapy. Therefore, this review summarizes and concludes the natural products that reportedly improve cancer immunotherapy and investigates the mechanism. And we found that saponins, polysaccharides, and flavonoids are mainly three categories of natural products, which reflected significant effects combined with cancer immunotherapy through reversing the tumor-immunosuppressive microenvironment. Besides, this review also collected the studies about nano-technology used to improve the disadvantages of natural products. All of these studies showed the great potential of natural products in cancer immunotherapy.
癌症免疫疗法已成为新一代抗肿瘤治疗方法,但其适应症仍集中在对免疫系统敏感的几种肿瘤类型上。因此,能够扩大其适应症并提高其疗效的有效策略成为癌症免疫疗法进一步发展的关键因素。据报道,天然产物对癌症免疫疗法有这种作用,包括癌症疫苗、免疫检查点抑制剂和过继性免疫细胞疗法。其机制主要归因于肿瘤免疫抑制微环境的重塑,这是协助肿瘤逃避免疫系统和癌症免疫疗法识别与攻击的关键因素。因此,本综述总结并归纳了据报道可改善癌症免疫疗法的天然产物,并研究了其机制。我们发现皂苷、多糖和黄酮类化合物是主要的三类天然产物,它们通过逆转肿瘤免疫抑制微环境,在与癌症免疫疗法联合应用时显示出显著效果。此外,本综述还收集了有关用于改善天然产物缺点的纳米技术的研究。所有这些研究都表明天然产物在癌症免疫疗法中具有巨大潜力。
Acta Pharm Sin B. 2022-3
Acta Pharm Sin B. 2021-4
Hum Vaccin Immunother. 2015
Bioact Mater. 2020-12-26
Gene. 2013-4-6
Comput Struct Biotechnol J. 2019-5-23
J Bone Oncol. 2019-3-19
Cancer Gene Ther. 2025-7-14
ACS Appl Mater Interfaces. 2025-7-23
Theranostics. 2025-6-9
Signal Transduct Target Ther. 2021-2-20
Nat Rev Microbiol. 2021-4
Nat Rev Drug Discov. 2020-11
Nat Commun. 2020-7-3